UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 84

Sortiert nach

SAKK57/16 Nab-paclitaxel and Gemcitabine in Soft Tissue Sarcoma (NAPAGE): a phase I/II trial

European journal of cancer (1990), 2024-01, Vol.197, p.113470-113470, Article 113470

2024

Volltextzugriff (PDF)

Successful treatment with an anti-PD-1 antibody for progressing brain metastases in renal cell cancer

Annals of oncology, 2016-03, Vol.27 (3), p.544-545

2016

Volltextzugriff (PDF)

5 Mechanisms of action in modern RCC treatment

Critical reviews in oncology/hematology, 2011, Vol.78, p.S4-S5

Rothermundt, C

2011

Volltextzugriff (PDF)

What is the role of routine follow-up for localised limb soft tissue sarcomas? A retrospective analysis of 174 patients

British journal of cancer, 2014-05, Vol.110 (10), p.2420-2426

2014

Volltextzugriff (PDF)

First-line treatment of metastatic clear cell renal cell carcinoma: a decision-making analysis among experts

ESMO open, 2021-02, Vol.6 (1), p.100030, Article 100030

2021

Volltextzugriff (PDF)

Antiangiogenic Drugs in Oncology: A Focus on Drug Safety and the Elderly – A Mini-Review

Gerontology (Basel), 2010-04, Vol.56 (3), p.303-309

2010

Volltextzugriff (PDF)

Assessment of anticancer-treatment outcome in patients with metastatic castration-resistant prostate cancer—going beyond PSA and imaging, a systematic literature review

Annals of oncology, 2015-11, Vol.26 (11), p.2221-2247

2015

Volltextzugriff (PDF)

Humoral and cellular responses to mRNA-based COVID-19 booster vaccinations in patients with solid neoplasms under active treatment

ESMO open, 2022-10, Vol.7 (5), p.100587-100587, Article 100587

2022

Volltextzugriff (PDF)

1594 Adherence to oral antineoplastic agents: Evaluation of a multi-centre, multidisciplinary training program for doctors and nurses

European journal of cancer (1990), 2015-09, Vol.51, p.S236-S236

2015

Volltextzugriff (PDF)

‘Sunitinib withdrawal phenomenon’ or spontaneous regression in renal cell cancer

Annals of oncology, 2009-06, Vol.20 (6), p.1144-1146

2009

Volltextzugriff (PDF)

Second-line treatment for metastatic clear cell renal cell cancer: experts’ consensus algorithms

World journal of urology, 2017-04, Vol.35 (4), p.641-648

2017

Volltextzugriff (PDF)

2500 Orteronel (Ort) maintenance therapy in patients (pts) with metastatic castration resistant prostate cancer (mCRPC) and non-progressive disease after first-line docetaxel (Doc) therapy: Results of a multicenter randomized double-blind placebo-controlled phase III trial (SAKK 08/11)

European journal of cancer (1990), 2015-09, Vol.51, p.S473-S473

2015

Volltextzugriff (PDF)

Multidrug and toxin extrusion 1 and human organic cation transporter 1 polymorphisms in patients with castration-resistant prostate cancer receiving metformin (SAKK 08/09)

Prostate cancer and prostatic diseases, 2015-06, Vol.18 (2), p.167-172

2015

Volltextzugriff (PDF)

1401 POSTER DISCUSSION Choi Response Criteria for Prediction of Clinical Outcome in Patients With Metastatic Renal Cell Carcinoma Treated With Targeted Therapies

European journal of cancer (1990), 2011, Vol.47, p.S169-S169

2011

Volltextzugriff (PDF)

Impact of the addition of metformin (Met) to abiraterone (Abi) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) progressing on Abi treatment: A phase II pilot study

Annals of oncology, 2017-09, Vol.28, p.v275-v275

2017

Volltextzugriff (PDF)

Combination chemotherapy with carboplatin, capecitabine and epirubicin (ECarboX) as second- or third-line treatment in patients with relapsed ovarian cancer: a phase I II trial

British journal of cancer, 2006-01, Vol.94 (1), p.74-78

2006

Volltextzugriff (PDF)

Treatment outcomes of men with stage 2 non-seminomatous germ cell tumours treated with primary retroperitoneal lymph node dissection: A systematic review

European urology open science (Online), 2022-11, Vol.45, p.S214-S215

2022

Volltextzugriff (PDF)

P095 - Screening is associated with lower mastectomy rates in Switzerland

Breast (Edinburgh), 2019-03, Vol.44, p.S47-S47

2019

Volltextzugriff (PDF)

Screening is associated with lower mastectomy rates in Switzerland

Breast (Edinburgh), 2019-03, Vol.44, p.S47

2019

Volltextzugriff (PDF)

An international expanded-access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy

European journal of cancer (1990), 2012-02, Vol.48 (3), p.324-332

2012

Volltextzugriff (PDF)

Earlier detection of recurrences using serum micro-RNA371 during active surveillance in men with stage I testicular germ cell tumours

European urology open science (Online), 2021-11, Vol.33, p.S345

2021

Volltextzugriff (PDF)

Fortschritte in der zytostatischen und supportiven Therapie des Pankreaskarzinoms

Onkologie (Heidelberg, Germany), 1999-03, Vol.5 (3), p.221-226

1999

Volltextzugriff (PDF)

Cetuximab in combination with docetaxel in patients (pts) with metastatic castration resistant (mCRPC) and docetaxel-refractory prostate cancer: A multicenter phase II trial (SAKK 08/07)

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.4666-4666

2010

Volltextzugriff (PDF)

Everolimus as first-line therapy in nonrapidly progressive metastatic castration-resistant prostate cancer (mCRPC): A multicenter phase II trial (SAKK 08/08)

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.4588-4588

2011

Volltextzugriff (PDF)

Phase I feasibility study of carboplatin plus capecitabine followed by maintenance capecitabine in patients (pts) with recurrent platinum-sensitive epithelial ovarian cancer (EOC)

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.5564-5564

2009

Volltextzugriff (PDF)

1 – 25 von 84

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(81)
Mit Volltextzugriff
(81)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(43)
Humans
(42)
Life Sciences & Biomedicine
(41)
Male
(32)
Female
(29)
Adult
(26)
Middle Aged
(23)
Psychiatry
(20)
Biological And Medical Sciences
(18)
Oncology
(16)
Medical Sciences
(15)
Schizophrenia
(15)
Aged
(11)
Neurosciences & Neurology
(10)
Neurosciences
(9)
Psychology. Psychoanalysis. Psychiatry
(9)
Schizophrenia - Blood
(9)
Young Adult
(9)
Adult And Adolescent Clinical Studies
(8)
Psychopathology. Psychiatry
(8)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

SAKK57/16 Nab-paclitaxel and Gemcitabine in Soft Tissue Sarcoma (NAPAGE): a phase I/II trial

Successful treatment with an anti-PD-1 antibody for progressing brain metastases in renal cell cancer

5 Mechanisms of action in modern RCC treatment

What is the role of routine follow-up for localised limb soft tissue sarcomas? A retrospective analysis of 174 patients

First-line treatment of metastatic clear cell renal cell carcinoma: a decision-making analysis among experts

Antiangiogenic Drugs in Oncology: A Focus on Drug Safety and the Elderly – A Mini-Review

Assessment of anticancer-treatment outcome in patients with metastatic castration-resistant prostate cancer—going beyond PSA and imaging, a systematic literature review

Humoral and cellular responses to mRNA-based COVID-19 booster vaccinations in patients with solid neoplasms under active treatment

1594 Adherence to oral antineoplastic agents: Evaluation of a multi-centre, multidisciplinary training program for doctors and nurses

‘Sunitinib withdrawal phenomenon’ or spontaneous regression in renal cell cancer

Second-line treatment for metastatic clear cell renal cell cancer: experts’ consensus algorithms

2500 Orteronel (Ort) maintenance therapy in patients (pts) with metastatic castration resistant prostate cancer (mCRPC) and non-progressive disease after first-line docetaxel (Doc) therapy: Results of a multicenter randomized double-blind placebo-controlled phase III trial (SAKK 08/11)

Multidrug and toxin extrusion 1 and human organic cation transporter 1 polymorphisms in patients with castration-resistant prostate cancer receiving metformin (SAKK 08/09)

1401 POSTER DISCUSSION Choi Response Criteria for Prediction of Clinical Outcome in Patients With Metastatic Renal Cell Carcinoma Treated With Targeted Therapies

Impact of the addition of metformin (Met) to abiraterone (Abi) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) progressing on Abi treatment: A phase II pilot study

Combination chemotherapy with carboplatin, capecitabine and epirubicin (ECarboX) as second- or third-line treatment in patients with relapsed ovarian cancer: a phase I II trial

Treatment outcomes of men with stage 2 non-seminomatous germ cell tumours treated with primary retroperitoneal lymph node dissection: A systematic review

P095 - Screening is associated with lower mastectomy rates in Switzerland

Screening is associated with lower mastectomy rates in Switzerland

An international expanded-access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy

Earlier detection of recurrences using serum micro-RNA371 during active surveillance in men with stage I testicular germ cell tumours

Fortschritte in der zytostatischen und supportiven Therapie des Pankreaskarzinoms

Cetuximab in combination with docetaxel in patients (pts) with metastatic castration resistant (mCRPC) and docetaxel-refractory prostate cancer: A multicenter phase II trial (SAKK 08/07)

Everolimus as first-line therapy in nonrapidly progressive metastatic castration-resistant prostate cancer (mCRPC): A multicenter phase II trial (SAKK 08/08)

Phase I feasibility study of carboplatin plus capecitabine followed by maintenance capecitabine in patients (pts) with recurrent platinum-sensitive epithelial ovarian cancer (EOC)

Suchergebnisse filtern